$AYTU falling wedge monthly Doji candle on support $AYTU looking for a reversal here earning on the 10th of February interesting pipeline could be huge profits to be made
falling wedge forming monthly Doji on support
−4.05USD
−17.05 MUSD
107.40 MUSD
5.36 M
About Aytu BioPharma, Inc.
Sector
CEO
Joshua R. Disbrow
Headquarters
Englewood
Website
Employees (FY)
150
Founded
2002
ISIN
US0547548588
FIGI
BBG000VC2PT9
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AYTU is 2.87 USD — it has increased by 0.47% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aytu BioPharma, Inc. stocks are traded under the ticker AYTU.
Aytu BioPharma, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Aytu BioPharma, Inc. has a max estimate of 8.00 USD and a min estimate of 8.00 USD.
AYTU earnings for the last quarter are −1.48 USD whereas the estimation was −0.04 USD which accounts for −3.60 K% surprise. Estimated earnings for the next quarter are −0.25 USD. See more details about Aytu BioPharma, Inc. earnings.
Aytu BioPharma, Inc. revenue for the last quarter amounts to 22.10 M USD despite the estimated figure of 27.73 M USD. In the next quarter revenue is expected to reach 21.75 M USD.
Yes, you can track Aytu BioPharma, Inc. financials in yearly and quarterly reports right on TradingView.
AYTU stock has fallen by 12.13% compared to the previous week, the month change is a 1.89% rise, over the last year Aytu BioPharma, Inc. has showed a 4.86% increase.
Like other stocks, AYTU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aytu BioPharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 150.00 employees. See our rating of the largest employees — is Aytu BioPharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aytu BioPharma, Inc. EBITDA is 3.32 M USD, and current EBITDA margin is −3.27%. See more stats in Aytu BioPharma, Inc. financial statements.